-transparent.png){kind=logo}
Sera from 62 patients with osteogenic sarcoma and 12 with malignant giant-cell tumour were tested for the presence of immune complexes by the 125I-Clq binding assay. Elevated serum Clq binding activity was found in 67.7% of the osteogenic sarcoma patients and in 75% of the giant-cell tumour patients. These results were compared with those obtained with five sera from patients with benign bone tumours and 20 sera from normal young donors. In the last two groups, the incidence of elevated Clq-binding activity was 0% and 5%, respectively. In some patients with giant-cell tumours, pre- and post-operative serum samples were studied, showing a decrease in test values after tumour resection. Preliminary sequential studies of individual patients indicate that the 125I-Clq binding assay may be useful for monitoring patients with bone tumours.
A S Eiras, and
R A Robins, and
R W Baldwin, and
V S Byers
June 1981,
The British journal of surgery,
A S Eiras, and
R A Robins, and
R W Baldwin, and
V S Byers
July 1980,
Clinical nephrology,
A S Eiras, and
R A Robins, and
R W Baldwin, and
V S Byers
January 1984,
Yonsei medical journal,
A S Eiras, and
R A Robins, and
R W Baldwin, and
V S Byers
January 1984,
Revista espanola de oncologia,
A S Eiras, and
R A Robins, and
R W Baldwin, and
V S Byers
January 1986,
Sovetskaia meditsina,
A S Eiras, and
R A Robins, and
R W Baldwin, and
V S Byers
January 1986,
Acta Universitatis Carolinae. Medica,
A S Eiras, and
R A Robins, and
R W Baldwin, and
V S Byers
January 1979,
Acta neurochirurgica. Supplementum,
A S Eiras, and
R A Robins, and
R W Baldwin, and
V S Byers
January 1981,
Neoplasma,
A S Eiras, and
R A Robins, and
R W Baldwin, and
V S Byers
April 1983,
American journal of surgery,
A S Eiras, and
R A Robins, and
R W Baldwin, and
V S Byers
October 1980,
Annals of the rheumatic diseases,
